¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"T-Cell Antigen Receptor Specificity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • spare receptor
    ¿©ºÐ¼ö¿ëü
  • scavenger receptor
    û¼ÒÁ¦¼ö¿ëü
  • stretch receptor
    »¸Ä§¼ö¿ë±â, ½ÅÀå¼ö¿ë±â
  • sensory receptor
    °¨°¢¼ö¿ë±â
  • silent receptor
    ¹«¹ÝÀÀ¼ö¿ëü
  • taste receptor
    ¹Ì°¢¼ö¿ë±â
  • T-cell receptor
    T¼¼Æ÷¼ö¿ëü
  • tactile receptor
    Ã˰¢¼ö¿ë±â
  • vasopressor receptor
    Ç÷¾Ð»ó½Â¼ö¿ëü
  • visual receptor
    1. ½Ã°¢¼ö¿ë±â 2. °¨±¤Ã¼
  • volume receptor
    ¿ëÀû¼ö¿ë±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÀ°Á¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü
  • receptor potential
    °¨¼ö±âÀüÀ§, °¨¼ö±âÀü¾Ð, ¼ö¿ëüÀü¾Ð
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
  • sensory receptor
    °¨°¢¼ö¿ëü
  • silent receptor
    ¹«¹ÝÀÀ¼ö¿ëü
  • spare receptor
    ¿©ºÐ¼ö¿ëü
  • stretch receptor
    »¸Ä§¼ö¿ëü, ½ÅÀå¼ö¿ëü
  • tactile receptor
    Ã˰¢¼ö¿ëü
  • taste receptor
    ¹Ì°¢¼ö¿ëü
  • tension receptor
    Àå·Â¼ö¿ëü
  • vasopressor receptor
    Ç÷°ü¼öÃà¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
  • CA 19-9 antigen
    CA 19-9 Ç׿ø
  • CA 50 antigen
    CA 50 Ç׿ø
  • CA-2<>
    CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
  • CD5 antigen
    CD5 Ç׿ø
  • CEA(carcinoembryonic antigen)
    žƼº¾ÏÇ׿ø
  • Cartwright antigen
    īƮ¶óÀÌÆ®Ç׿ø
  • Cha antigen
    Cha Ç׿ø
  • Chido (Ch") antigen
    Chido(Ch") Ç׿ø
  • D antigen
    D Ç׿ø
  • D antigen
    DÇ׿ø
  • D-related antigen
    D-°ü·ÃÇ׿ø
  • DP antigen
    DPÇ׿ø
  • DQ antigen
    DQÇ׿ø
  • DR antigen
    DRÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • free receptor
    À¯¸®¼ö¿ëü(¡­áôé»ô÷).
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • hormone receptor
    È£¸£¸ó¼ö¿ëü.
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • influenza virus receptor
    ÀÎÇ÷翣ÀÚ¹ÙÀÌ·¯½º ¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • interferon (INF) receptor
    ÀÎÅÍÆä·Ð ¼ö¿ëü
  • kapa receptor
    Ä«ÆÄ ¼ö¿ëü
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ë±â
  • maltose channel (lamda receptor)
    ¸»Å佺Åë·Î (¶÷´Ù¼ö¿ëü)
  • mmuscle receptor
    ±Ù°¨¼ö±â
  • mu receptor
    ¹Â¼ö¿ëü
  • muscarinic receptor
    ¹«½ºÄ«¸° ¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±Ù¼ö¿ëü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • fluorescent antigen
    Çü±¤ Ç׿ø(û«ÎÃù÷ê«)
  • H antigen
    H Ç׿ø(ù÷ê«)
  • haptenic antigen
    ÇÕÅÙ Ç׿ø(ù÷ê«)
  • hepatitis B surface antigen
    BÇü(úþ) °£¿°(ÊÜæú) Ç¥¸é Ç׿ø(øúØüù÷ê«)
  • heterogenetic antigen
    ÀÌÁ¾ Ç׿ø(ì¶ðúù÷ê«)
  • heterophile antigen
    ÀÌÈ£¼º Ç׿ø(ì¶û¿àõù÷ê«)
  • hexon antigen
    Çí¼Õ Ç׿ø(ù÷ê«)
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕ¼º Ç׿ø(ðÚòÄîêùêàõù÷ê«)
  • Ia antigen
    Ia Ç׿ø(ù÷ê«)
  • incomplete antigen
    ºÒ¿ÏÀü Ç׿ø(ÝÕèÇîïù÷ê«)
  • K antigen
    K Ç׿ø
  • LS antigen
    LS Ç׿ø(ù÷ê«)
  • M antigen
    M Ç׿ø(ù÷ê«)
  • MHC antigen
    MHCÇ׿ø(ù÷ê«)
  • NP antigen
    NPÇ׿ø(ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CCA cephalin cholesterol antigen; chick cell agglutination; chimpanzee coryza agent; choriocarcinoma; ci...
EMA electronic microanalyzer; emergency medical assistance, emergency medical assistant; endothelial mon...
GSA general somatic afferent; group-specific antigen; Gross virus antigen; guanidinosuccinic acid
HA H antigen; Hakim-Adams [syndrome]; halothane anesthesia; Hartley [guinea pig]; headache; health alli...
HAA hearing aid amplifier; hemolytic anemia antigen; hepatitis-associated antigen; hospital activity ana...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
VCA Anti-viral capsid antigen
anti-HBc Antibodies to hepatitis B core antigen
anti HBc Antibody to hepatitis B core antigen
anti-HBe Antibody to hepatitis B e antigen
anti HBs Antibody to hepatitis B surface antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen shift
    Ç׿ø ´ëº¯ÀÌ
  • antigen unit
    Ç׿ø ´ÜÀ§
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • carcinoembryonic antigen assay
    ¾Ï ¹è¾Æ¼º Ç׿ø ÃøÁ¤, ¾Ï¼º ¹è¾Æ¼º Ç׿ø ÃøÁ¤
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • dander antigen
    Àμ³ Ç׿ø
    ÇǺÎÀÇ Ç¥¸éÀ¸·ÎºÎÅÍ ²÷ÀÓ¾øÀÌ »êÆ÷µÇ°í ÀÖ´Â ¹°ÁúÀÇ È¥ÇÕ¹°. ¹Ú¸®µÈ »óÇÇ ¼¼¹Î, ÅÐÀÇ ´ÜÆí, ÇǺÎÀÇ Áö¹æ µîÀÌ Æ÷ÇԵǴµ¥ ƯÈ÷ Àμ³ÀÌ Áß¿äÇÏ´Ù. ¾ÆÅäÇǰ¡ ÀÖ´Â »ç¶÷¿¡¼­´Â Áï½ÃÇü °ú¹ÎÁõÀÇ ¿øÀÎÀÌ µÇ´Â ¼ö°¡ ÀÖ´Ù.
  • determinant antigen
    Ç׿ø °áÁ¤±º, °áÁ¤ Ç׿ø
    ¸é¿ªÇÐÀû ƯÀ̼ºÀ» °áÁ¤Çϴ ƯÁ¤ÀÇ È­ÇÐÀûÀÎ ºÐÀÚ±º.
  • diego antigen
    µð¿¡°í Ç׿ø
  • differentiation antigen
    ºÐÈ­ Ç׿ø
    ¼¼Æ÷°¡ ºÐÈ­ÇØ °¡´Âµ¥ À־ Ç¥ÇöµÇ´Â ¼¼Æ÷¸· »óÀÇ Ç׿ø. T ¼¼Æ÷¿¡¼­´Â B ¼¼Æ÷·ÎºÎÅÍ ±¸º°ÇÏ´Â ºÐÈ­ Ç׿øÀº mouse »çÀÌ¿¡¼­ ¼¼Æ÷¸¦ Åõ¿©ÇÏ¿© ¸¸µé¾îÁø µ¿Á¾ Ç×Ç÷û¿¡ ÀÇÇÏ¿© °ËÃâµÇ´Â Ç׿ø
  • DR antigen
    DR Ç׿ø
    HLA-D ¿µ¿ª À¯ÀüÀÚÀÇ Áö¹è¸¦ ¹Þ´Â Ç׿øÀ̸ç, ÁÖ·Î B ¼¼Æ÷ ¹× macro
  • endogenous antigen
    ³»ºÎ Ç׿ø
    µ¿¹°ÀÇ Ã¼³»¿¡ Á¸ÀçÇÏ´Â °Íµé·Î¼­ µ¿¹°ÀÇ Á¶Á÷, ¼¼Æ÷ÀÇ ÀϺΠ±¸¼º ¼ººÐ µîÀÌ ¿©±â¿¡ ¼ÓÇÑ´Ù.
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • fetal antigen
    ÅÂ¾Æ Ç׿ø
    Á¾¾ç °ü·Ã Ç׿øÀÇ ÀÏÁ¾, Å»ý±â Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö¸¸, Á¤»óÀûÀÎ ºÐÈ­¸¦ ¹âÀº Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö ¾Ê°Å³ª ±ØÈ÷ ¹Ì·® Á¸ÀçÇϰųª ÇÑ´Ù.
  • H antigen
    H Ç׿ø
    1. ¿îµ¿¼º ¼¼±ÕÀÇ Æí¸ð Ç׿ø 2. H-¹°Áú.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
presynaptic receptor <physiology> Receptors located on presynaptic terminals at synapses.
(05 Mar 1998)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
Xiphophorus melanoma receptor kinase <enzyme> Growth factor receptor protein with an extracellular ligand binding domain and an intracellular catalytic domain
Registry number: EC 2.7.1.-
Synonym: xmrk protein
(26 Jun 1999)
selective oestrogen-receptor modulator <pharmacology> An antioestrogen which possesses some, but not all, of the actions of oestrogen. For example, raloxifene (evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus.
Acronym: SERM
(17 Jul 2002)
hormone receptor assay A diagnostic test to determine whether a breast cancer's growth is influenced by hormones or if it can be treated with hormones.
(09 Oct 1997)
purinergic receptor <biochemistry> Receptors that use purine nucleotides (e.g. ATP) as ligands.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
S-receptor kinase <enzyme> Srk - s-receptor kinase; from brassica oleracea; amino acid sequence has been determined
Registry number: EC 2.7.1.-
Synonym: srk gene product
(26 Jun 1999)
steroid receptor Family of nuclear transcription factors, most of which are receptors for hormones of the steroid family, for example androgen, oestrogen, glucocorticoid, mineralocorticoid, progesterone, retinoic acid, ecdysone, thyroid hormone and the Drosophila transcription factors knirps, ultraspiracle and seven up. This family contains a conserved domain (the steroid finger motif) containing two C4 type zinc fingers.
(18 Nov 1997)
nicotinic acetylcholine receptor Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range).
(18 Nov 1997)
nicotinic cholinergic receptor A class of receptors responsive to acetylcholine that also are activated by nicotine; ganglionic (including the adrenal medulla) and neuromuscular receptors. Two classes exist: nicotinic-neuronal and nicotinic-muscular.
(05 Mar 2000)
NMDA receptor A type of glutamate receptor that participates in excitatory neurotransmission and also binds N-methyl-d-aspartate; may be particularly involved in the cell damage observed in individuals with Huntington's disease.
(05 Mar 2000)
N methyl D aspartate receptor <physiology> Glutamate receptor sub type (see excitatory amino acids). N methyl D aspartate receptor channels seem to be potentiated by intracellular arachidonic acid.
Acronym: NMDA
(26 Mar 1998)
quisqualate receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
insulin receptor Areas on the outer part of a cell that allow the cell to join or bind with insulin that is in the blood. When the cell and insulin bind together, the cell can take glucose (sugar) from the blood and use it for energy.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á